Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study-Reference-Cited by-同舟云学术

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

Published:2009-09-28 Issue:1 Volume:9 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Lièvre Astrid,Samalin Emmanuelle,Mitry Emmanuel,Assenat Eric,Boyer-Gestin Christine,Lepère Céline,Bachet Jean-Baptiste,Portales Fabienne,Vaillant Jean-Nicolas,Ychou Marc,Rougier Philippe

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/article/10.1186/1471-2407-9-347/fulltext.html

Reference34 articles.

1. de Gramont A, Figer A, Seymour M, Homerin M, Hmissi A, Cassidy J, Boni C, Cortes-Funes H, Cervantes A, Freyer G, et al: Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 2000, 18 (16): 2938-2947.

2. Douillard JY, Cunningham D, Roth AD, Navarro M, James RD, Karasek P, Jandik P, Iveson T, Carmichael J, Alakl M, et al: Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer: a multicentre randomised trial. Lancet. 2000, 355 (9209): 1041-1047. 10.1016/S0140-6736(00)02034-1.

3. Goldberg RM, Sargent DJ, Morton RF, Fuchs CS, Ramanathan RK, Williamson SK, Findlay BP, Pitot HC, Alberts SR: A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol. 2004, 22 (1): 23-30. 10.1200/JCO.2004.09.046.

4. Saltz LB, Cox JV, Blanke C, Rosen LS, Fehrenbacher L, Moore MJ, Maroun JA, Ackland SP, Locker PK, Pirotta N, et al: Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. Irinotecan Study Group. N Engl J Med. 2000, 343 (13): 905-914. 10.1056/NEJM200009283431302.

5. Ferrara N: Molecular and biological properties of vascular endothelial growth factor. J Mol Med. 1999, 77 (7): 527-543. 10.1007/s001099900019.

Cited by 47 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Chemotherapy re-use versus anti-angiogenic monotherapy as the third-line treatment of patients with metastatic colorectal cancer: a real-world cohort study;BMC Cancer;2024-03-05

2. A Real-World Study of Safety, Immunogenicity and Efficacy of Bevacizumab in Patients With Solid Malignancies: A Phase IV, Post-Marketing Study in India;Cancer Informatics;2023-01

3. Efficacy of Retreatment with Oxaliplatin-Based Regimens in Metastatic Colorectal Cancer Patients: The RETROX-CRC Retrospective Study;Cancers;2022-02-25

4. Chemotherapeutic Protocols for the Treatment of Gastrointestinal Tract Cancer;Chemotherapy Protocols and Infusion Sequence;2022

5. Patient demographics and management landscape of metastatic colorectal cancer in the third‐line setting: Real‐world data in an australian population;Asia-Pacific Journal of Clinical Oncology;2021-04-18